May. 16, 2025 at 2:03 PM ET7 min read

GMED’s Stock Buyback: Time to Reconsider?

Tim BohenAvatar
Written by Tim Bohen Reviewed by Ben Sturgill Fact-checked by Ellis Hobbs

Globus Medical Inc.’s stocks have been trading up by 5.24 percent, reflecting renewed investor confidence.

Globe Medical’s Financial Moves

  • A notable move by Globus Medical is their announcement of a $500M share repurchase program, which was immediately reflected in a 3.8% boost in after-hours trading. Such buybacks can show investor confidence and may lead to stronger stock performance in the near future.

  • The firm experienced a string of price target reductions by multiple financial institutions following underperformance in their first-quarter reports. Despite this, RBC Capital has maintained an Outperform rating, hinting that the post-earning decline might be an overreaction, encouraging investors to consider buying on current weaknesses.

  • Similarly, Piper Sandler and Roth Capital decreased their price targets for GMED, citing subdued results due to enabling technology sales and other integration-related issues. Yet, they hold steady on their Buy ratings, shedding light on potential growth prospects.

  • Morgan Stanley, aligning with the trend, also reduced its price target from $100 to $75 but sees a bright outlook if issues are resolved, evidenced by their continued Overweight rating.

  • Truist Securities conveyed a significant drop in stock ratings but still observed GMED’s prospects as positive, albeit with a hold recommendation. The stock, which was trading at a lower price point, sees potential for upward momentum once critical concerns are addressed.

Candlestick Chart

Live Update At 14:02:31 EST: On Friday, May 16, 2025 Globus Medical Inc. stock [NYSE: GMED] is trending up by 5.24%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quarterly Earnings and Financial Analysis

When analyzing potential trades, it’s crucial for traders to have a clear strategy and understanding of the market to avoid unnecessary risks. As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” This principle can guide traders to be more disciplined, ensuring they only act when their decisions are based on solid data and confident insights rather than speculation and assumptions. This approach not only minimizes uncertainties but also enhances the likelihood of successful trading outcomes.

Globus Medical’s recent earnings release gives us a peek into their current standing. First-quarter financial results weren’t quite as inspiring as hoped, causing ripples in stock movements. Revenue landed at $598.12M, showing a slight underperformance compared to expectations. When diving into key ratios, their gross margin stands strong at 60.6%, underscoring efficiency, despite other obstacles.

With EBIT margins at 9.3% and EBITDA margins at 27.4%, it’s evident GMED remains profitable, though improvements can still be made. Their profitability ratios, though decent, need a boost for future assurance. Revenue per share hit $18.61, hinting at solid positioning, yet the recent challenges with tech sales and supply disruptions shed light on areas needing fortification.

A closer look at financial strength shows a commendable current ratio of 4.5, indicating good liquidity. However, reduced Q1 sales, partially due to slower enabling technology sales, have left their mark. Analysts have highlighted these weaker-than-expected sales as a driving force behind their lowered price targets.

The balance sheet emphasizes the company’s structural strengths. With an impressive quick ratio of 1.4, GMED is well-prepared for short-term obligations. The leverage ratio at 1.2 further underscores their fiscal discipline. The intrepid management effectiveness, with return on equity peaking at 5.4%, shows the effectiveness in utilizing assets for profit, despite hiccups in specific business areas.

More Breaking News

In terms of valuation, the price-to-earnings (PE) ratio sits at 43.15, somewhat high, but indicative of potential growth valued by the market. This, alongside a market cap showcasing robust enterprise value, projects stability moving forward, as they continue to navigate bumps on the journey.

Impact of Recent News on Price Movements

The revelation of an expansive $500M buyback paints a picture of a company devoted to shoring up its stock stability, reassuring investors amid recent fluctuations. This move stimulated a tangible increase in stock valuation, as illustrated by the after-hours hike. It’s a strategic move likely aimed at solidifying shareholder value and fortifying market confidence.

Meanwhile, RBC Capital and other firms, although reducing their price targets following subdued earnings, continue to support their positive long-term view of GMED. The company’s resilience despite quarterly hurdles presumably encourages analysts to maintain their optimism. The recommended “Buy on weakness” angle acknowledges prevalent issues while recognizing the potential bounce-back capacity.

Simultaneously, agencies like Piper Sandler and Roth Capital echo this sentiment, underscoring improvement areas such as integrating tech components and distributor timelines, which, while challenging now, lay groundwork for eventual resurgence.

Morgan Stanly’s tempered optimism and price target readjustment highlight enduring faith in Globus Medical’s capacity to tackle its constraints, and the lowered targets from Truist and others mirror these sentiments, hinting at stabilized performance once hurdles are navigated.

The collection of news opens a spectrum of insights — bolstering of stock value through buyback initiatives and price target modifications reflect corporate resilience and market adaptability. The complex dance of expectations and delivered outcomes finds GMED poised at a junction of opportunity.

Navigating GMED’s Path Forward

From the lens of a seasoned financial observer, Globus Medical stands amid challenges with a compass set for possible recovery. While softened earnings shook the confidence a tad, buyback measures and continued analyst support lay a potential foundation for growth and sustained performance.

Future growth hinges on resolving current integrative issues and amplifying technology sales. The reported structural strengths displayed on the balance sheet grant them a robust cushion, while buying back stocks may ensure a narrowing of price discrepancies, offering a clearer path toward value realization.

The shift of market forces and analyst perspectives, while cautious, aren’t entirely bearish, highlighting a delicate balance between momentary setbacks and future promise. GMED’s ongoing navigation through these dynamics offers rich potential for both moderate gains and the prospect of robust recovery if strategies align favorably.

As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” Watching these patterns emerge, traders can capitalize on the unfolding narrative of Globus Medical’s ascension, backed by strategic initiatives amidst a climate charged with anticipation.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.